Foundayo (orforglipron)

Foundayo (Orforglipron)

Foundayo (orforglipron) is an oral GLP-1 receptor agonist authorised in the UK for weight management and for improving glycaemic control in adults with insufficiently controlled type 2 diabetes.

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised Foundayo on 10 August 2026. The UK became the first country in Europe to authorise orforglipron for these indications. ([MHRA](https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes))

What is Foundayo?

Foundayo contains orforglipron, an orally administered GLP-1 receptor agonist. Unlike injectable GLP-1 medicines, orforglipron is formulated as a tablet for oral administration.

For weight management, the MHRA has authorised orforglipron alongside a reduced-calorie diet and increased physical activity for eligible adults with obesity, or adults who are overweight and have at least one weight-related comorbidity.

It is also authorised to improve glycaemic control in adults with insufficiently controlled type 2 diabetes. ([MHRA](https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes))

How Does Orforglipron Work?

Orforglipron acts on the GLP-1 receptor, a pathway involved in appetite regulation and glucose metabolism. GLP-1 receptor agonism can influence appetite and food intake and can also contribute to improved blood-glucose control in appropriate patients.

Foundayo Dose Information

The appropriate Foundayo dose depends on the indication and the prescribing information applicable to the patient.

Do not use an overseas dosing schedule or change the prescribed dose without advice from your healthcare professional. The official UK Summary of Product Characteristics should be used for the current UK dosing instructions once published and available through the MHRA medicines database.

Who May Be Prescribed Foundayo?

For weight management, Foundayo is authorised for eligible adults with a BMI of 30 kg/m² or above, or a BMI between 27 kg/m² and 30 kg/m² with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.

Foundayo is also authorised for improving glycaemic control in adults with insufficiently controlled type 2 diabetes. ([MHRA](https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes))

Important Safety Information

• Foundayo is a prescription medicine and should be used under appropriate healthcare supervision.
• Use the medicine exactly as prescribed.
• Do not change the dose without speaking with your prescriber.
• Tell your healthcare professional about all medicines and supplements you take.
• Patients with diabetes may require monitoring of blood-glucose levels and adjustment of other diabetes medicines.
• GLP-1 receptor agonists can cause gastrointestinal adverse effects, including nausea, vomiting, diarrhoea and constipation.
• Seek medical advice if you develop severe or persistent symptoms.

Product Information

• Active ingredient: Orforglipron
• Drug class: GLP-1 receptor agonist
• Dosage form: Oral tablet
• Route of administration: Oral
• UK regulatory status: MHRA authorised
• Manufacturer/authorisation holder: Eli Lilly

Foundayo and Weight Management

For eligible adults using Foundayo for weight management, treatment forms part of a broader programme that includes dietary and physical-activity measures. The medicine should not be presented as a substitute for healthy eating, physical activity or professional medical care.

Related Products

For information about other prescription weight-management medicines, visit our Weight Management category.

You can also explore our Wegovy and Mounjaro pages for information about other authorised prescription treatments.

For general educational information, visit our Weight Management Guide.

Official UK Regulatory Information

The MHRA announcement on Foundayo confirms that orforglipron was authorised in the UK on 10 August 2026 for weight management and type 2 diabetes.

The MHRA states that safety and effectiveness of orforglipron will continue to be closely monitored.

Frequently Asked Questions

What is Foundayo?

Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist authorised for specific weight-management and type 2 diabetes indications.

What is the active ingredient in Foundayo?

The active ingredient is orforglipron.

Is Foundayo authorised in the UK?

Yes. The MHRA authorised Foundayo (orforglipron) in the UK on 10 August 2026 for weight management in eligible adults and for improving glycaemic control in adults with insufficiently controlled type 2 diabetes.

Is Foundayo an injection?

No. Foundayo is an oral medicine supplied as a tablet rather than a subcutaneous injection.

Who can use Foundayo for weight management?

The UK authorisation covers eligible adults with obesity, or adults who are overweight and have at least one weight-related comorbidity. A healthcare professional must determine whether treatment is appropriate.

Can I change my Foundayo dose myself?

No. Dose changes should only be made according to the official prescribing information and instructions from your healthcare professional.

Where can I find official information about Foundayo?

The MHRA provides the authoritative UK regulatory information for Foundayo. The official Summary of Product Characteristics and Patient Information Leaflet should be consulted for detailed prescribing and safety information.